Elisabeth I Heath

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi New targets in the management of prostate cancer
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA
    Hematol Oncol Clin North Am 20:985-99, xi. 2006
  2. ncbi A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors
    Elisabeth I Heath
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 71:565-73. 2013
  3. ncbi A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors
    Elisabeth I Heath
    Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, USA
    Invest New Drugs 30:1566-74. 2012
  4. ncbi A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
    Elisabeth I Heath
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 14:7940-6. 2008
  5. ncbi A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies
    Elisabeth I Heath
    Wayne State University Karmanos Cancer Institute, Detroit, MI 48201, USA
    Invest New Drugs 29:1426-31. 2011
  6. ncbi The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, Department of Hematology and Oncology, Wayne State University, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA
    Urology 71:151-5. 2008
  7. ncbi A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
    Elisabeth I Heath
    Wayne State University Karmanos Cancer Institute, 4100 John R, 4HWCRC, Detroit, MI 48201, USA
    Invest New Drugs 26:59-65. 2008
  8. ncbi A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
    E I Heath
    Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, Michigan, USA
    Clin Pharmacol Ther 88:818-23. 2010
  9. ncbi Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    J Natl Cancer Inst 99:545-57. 2007
  10. ncbi Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma
    Elisabeth I Heath
    Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    Invest New Drugs 24:135-40. 2006

Detail Information

Publications25

  1. ncbi New targets in the management of prostate cancer
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA
    Hematol Oncol Clin North Am 20:985-99, xi. 2006
    ..Efficient trial design, appropriate selection of correlative markers,and close toxicity monitoring will help improve our ability to identify promising novel agents...
  2. ncbi A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors
    Elisabeth I Heath
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 71:565-73. 2013
    ....
  3. ncbi A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors
    Elisabeth I Heath
    Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, USA
    Invest New Drugs 30:1566-74. 2012
    ..These changes in pharmacokinetic parameters were not associated with increases in the magnitude or duration of short-term (ie, up to 72 h) blood pressure elevation compared with whole-tablet administration...
  4. ncbi A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
    Elisabeth I Heath
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 14:7940-6. 2008
    ..A two-stage phase II study was conducted to assess the activity and toxicity profile of 17-AAG administered to patients with metastatic, hormone-refractory prostate cancer...
  5. ncbi A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies
    Elisabeth I Heath
    Wayne State University Karmanos Cancer Institute, Detroit, MI 48201, USA
    Invest New Drugs 29:1426-31. 2011
    ..The present study was designed to: (i) assess the safety and tolerability of BMS-275183, and (ii) determine a suitable Phase II dose of BMS-275183 when given on a continuous daily schedule to patients with advanced solid tumor(s)...
  6. ncbi The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, Department of Hematology and Oncology, Wayne State University, 4100 John R, 4 HWCRC, Detroit, MI 48201, USA
    Urology 71:151-5. 2008
    ..To test the accuracy of the 2001 Partin Tables in African American men who underwent radical prostatectomy at multiple centers throughout the United States...
  7. ncbi A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
    Elisabeth I Heath
    Wayne State University Karmanos Cancer Institute, 4100 John R, 4HWCRC, Detroit, MI 48201, USA
    Invest New Drugs 26:59-65. 2008
    ..The secondary objective was to assess the safety and tolerability of SNS-032 and to evaluate its bioavailability as an oral solution...
  8. ncbi A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
    E I Heath
    Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, Michigan, USA
    Clin Pharmacol Ther 88:818-23. 2010
    ..Therefore, pazopanib should be administered to patients in the fasted state so as to minimize within- and between-day variability in the systemic exposure to pazopanib in patients with cancer...
  9. ncbi Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    J Natl Cancer Inst 99:545-57. 2007
    ....
  10. ncbi Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma
    Elisabeth I Heath
    Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    Invest New Drugs 24:135-40. 2006
    ..The objectives of the trial were to determine pathologic complete response rate (pCR), overall response rate, progression-free survival, pattern of disease relapse, and two-year and overall survival...
  11. ncbi A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer
    Elisabeth I Heath
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Clin Prostate Cancer 4:138-41. 2005
  12. ncbi Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results
    Elisabeth I Heath
    Karmanos Cancer Institute, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 68:703-12. 2011
    ..To evaluate the maximum tolerated dose (MTD), safety, and antitumor activity of sunitinib combined with paclitaxel and carboplatin...
  13. ncbi Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience
    Elisabeth I Heath
    Division of Hematology and Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    J Biopharm Stat 19:414-23. 2009
    ..The theoretical advantages and disadvantages of both Phase I trial designs did not readily emerge in their actual application in clinical trials conducted at our institution...
  14. ncbi Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Shirish M Gadgeel
    Karmanos Cancer Institute Wayne State University, Detroit, Michigan, USA
    J Thorac Oncol 2:299-305. 2007
    ....
  15. ncbi Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors
    Patricia LoRusso
    Karmanos Cancer Institute, 4100 John R, 4 HWCRC, Detroit, MI, 48201, USA
    Invest New Drugs 26:455-62. 2008
    ..Hypertension was the most common related grade 3 event (21%). No grade 4 or 5 treatment-related adverse events occurred...
  16. ncbi A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer
    Elisabeth I Heath
    Karmanos Cancer Institute, Wayne State University Detroit, MI, USA
    Am J Transl Res 2:402-11. 2010
    ....
  17. ncbi Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus
    Elisabeth I Heath
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Invest New Drugs 20:95-9. 2002
    ..The objective of this trial was to determine the complete and partial response rate of docetaxel in patients with incurable adenocarcinoma of the esophagus...
  18. ncbi Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults
    Madhuri Bajaj
    Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA
    Expert Opin Biol Ther 11:1519-24. 2011
    ..Further clinical trials are underway evaluating the use of conatumumab in combination with chemotherapeutic and targeted agents...
  19. ncbi Angiogenesis inhibitors in the treatment of prostate cancer
    Clara Hwang
    Department of Internal Medicine, Henry Ford Hospital, CFP 559, 2799 West Grand Blvd, Detroit, MI 48202, USA
    J Hematol Oncol 3:26. 2010
    ..Ultimately, the fate of anti-angiogenic agents in prostate cancer rests on the eagerly anticipated results of several key phase III studies...
  20. ncbi Malignant undifferentiated sex cord-stromal testis tumor with brain metastasis: case report
    Priya G Kumaravelu
    Department of Internal Medicine, Wayne State University, Detroit, MI 48201, USA
    Urol Oncol 26:53-5. 2008
    ..To our knowledge, undifferentiated sex cord-stromal tumor with brain metastasis has not been reported. As with any new onset neurologic deficits in patients with solid tumors, the presence of brain metastases should be considered...
  21. ncbi Results from a prostate cancer admixture mapping study in African-American men
    Cathryn Hufford Bock
    Wayne State University School of Medicine, Detroit, MI 48201, USA
    Hum Genet 126:637-42. 2009
    ..In conclusion, we confirmed ancestry associations on 8q24, and identified additional ancestry-associated regions potentially harboring prostate cancer susceptibility loci...
  22. ncbi A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183
    Linda E Bröker
    VU University Medical Center, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 13:3906-12. 2007
    ..Additionally, the pharmacokinetics and possible antitumor activity were studied...
  23. ncbi The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate
    Elisabeth I Heath
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Clin Prostate Cancer 1:182-7. 2002
  24. ncbi Postesophagectomy morbidity, mortality, and length of hospital stay after preoperative chemoradiation therapy
    John R Doty
    Department of Surgery, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Ann Thorac Surg 74:227-31; discussion 231. 2002
    ..Squamous cell carcinoma patients are nearly twice as likely to develop postoperative complications and are more likely to have respiratory complications than adenocarcinoma patients...
  25. ncbi Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
    Duyen T Dang
    Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Cancer Res 68:1872-80. 2008
    ..The data further show that DPP4 is a novel marker of HIF-1 induction. Altogether, these preclinical findings suggest novel clinical trials for predicting and monitoring tumor vessel responses to antiangiogenic therapy...